Biotech

All Articles

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of considerable management hirings, shooting...

Lykos will definitely ask FDA to reexamine its choice observing being rejected of MDMA therapy for trauma

.Complying with an inadequate showing for Lykos Rehabs' MDMA applicant for trauma at a current FDA a...

AN 2 fifty percents head count, quits period 3 trial after records let down

.AN2 Therapeutics is actually reassessing its company in reaction to uninspired midphase information...

Merck spends $700M for bispecific, spying autoimmune opening and opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually paying $700 thousand beforehand to test Amgen in a blood cancer market. ...

Gilead pays J&ampJ $320M to leave licensing package for seladelpar

.Along With Gilead Sciences about to an FDA choice for its liver health condition medication seladel...

' All hands on deck' at Lilly as peers target excessive weight market

.CEO David Ricks may observe the providers putting together outdoors tents at basecamp behind Eli Li...

Entero giving up staff, leaving office as well as pausing R&ampD

.Bed Liquidators has actually transformed Entero Therapies white as a slab. The lender got Entero to...

Exelixis falls ADC after deciding it's no suit for Tivdak

.Exelixis is giving up on its own cells element (TF)- targeting antibody-drug conjugate after wrappi...

Relay loses interest in SHP2 inhibitor after Genentech leaves behind

.Three weeks after Roche's Genentech device walked away from an SHP2 prevention contract, Relay Reha...

Stoke's Dravet syndrome med discharged of predisposed professional hold

.Stoke Therapies' Dravet syndrome medicine has been freed from a partial grip, removing the techniqu...